PP2A has a very broad range of substrates, with specificity given by the subunit composition of the holoenzyme, and generally act as a tumor suppressor [157, 158]: for this reason a more sensible approaches for cancer treatment could be either to use pharmacological activators of specific PP2A isoforms [159, 160, 161], or to target its cellular inhibitors. The gene discussed is PTPA; the disease is neoplasm.